The management of B-cell lymphomas depends not only on how advanced they are but also on specific disease traits like growth speed (slow or fast) and molecular subtype. While DLBCL can be aggressive, some patients can achieve long-term survival but incomplete cure through chemotherapy. Germinal center B-cell (GCB)-like DLBCL patients usually respond well to R-CHOP given every 21 days. Rituximab targets CD20, a protein in B cells. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.